Huadong Medicine Co., Ltd (SHE: 000963), a pharmaceutical company based in China, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its antibody drug conjugate (ADC), HDM2005. This molecule targets recombinant receptor tyrosine kinase-like orphan receptor 1 (ROR1) and is intended for the treatment of a broad range of advanced malignant tumors.
Preclinical studies indicate that HDM2005’s antibody component specifically binds to tumor cells that express the relevant antigens. Once HDM2005 is internalized by these tumor cells, it releases cytotoxic agents that are designed to target and eliminate the cancer cells. The available data suggests that HDM2005 exhibits favorable pharmacological properties and a promising safety profile.- Flcube.com
